NAVER D2SF Backs ImpriMed in $10 Million Bridge Round

Sep 19, 2026
NAVER D2SF invested in precision medicine company ImpriMed through a $10 million Series A2 bridge round led by LB Investment.

NAVER D2SF said in a press release that it invested in Silicon Valley based precision medicine company ImpriMed through a $10 million Series A2 bridge round. LB Investment led the round, with participation from Samsung Securities, Alois Ventures, BonAngels and Han River Partners.

ImpriMed combines analysis of live patient cancer cells with genomic, immunophenotypic and clinical data to support cancer treatment decisions and drug development. Its xCellSense platform keeps cancer cells viable outside the body for testing biological characteristics and drug sensitivity. The company says its AI models are trained on more than 3.5 million data points.

The company plans to seek FDA clearance and CLIA certification by the first quarter of 2027 for products covering blood cancers and blood infections. It is also pursuing approval in South Korea for software that predicts multiple myeloma prognosis and therapy response.

We hope you enjoyed this article

Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Whitepaper

Tensordyne Napier: What If One Rack Could Do the Work of Nine?

Tensordyne

This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.